Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor Clinical Trial

Official title:
A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer

Status Completed

Clinical Trial Summary

Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Tumor

Clinical Trial Details

NCT number	NCT00502060
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 1
Start date	August 2004
Completion date	June 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05108779` - QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors	Phase 1
Recruiting	`NCT05607563` - A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours	Phase 1
Recruiting	`NCT05839106` - Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT02977156` - Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.	Phase 1